NDAINHALATIONAEROSOL, METERED
Approved
Nov 2018
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
4/8 — Partial
PRIMATENE MIST (epinephrine inhalation) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2018.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Primatene Mist is an inhaled epinephrine aerosol approved for acute bronchospasm relief in asthma patients. It works as an alpha-adrenergic agonist, stimulating adrenergic receptors to rapidly dilate airways and restore breathing. This metered-dose inhaler represents a non-prescription rescue therapy option.
Post-LOEPost-LOE
Post-LOE product with moderate competitive pressure (35/100) suggests stable but not growth-driven team size focused on retention and cost management.
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Pfizer is hiring 1 role related to this product
Worked on PRIMATENE MIST at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.